Alnylam releases positive top-collection data from ALN-TTRsc Stage I trial for TTR-mediated amyloidosis Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, announced today positive top-line results from its ongoing Stage I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treating TTR-mediated amyloidosis . The business can be reporting that ALN-TTRsc accomplished robust and statistically significant knockdown of serum TTR proteins levels of higher than 80 percent in healthy volunteer subjects, in line with outcomes for ALN-TTRsc reported in non-human primates previously ?sildenafil 100mg more info .

viagradanmark.eu

We have backorders currently, but this increased capability will fulfill these backorders. We ought to then have excess capability available for those that want masks for the forthcoming flu period/swine flu season. We are raising our manufacturing efforts to supply healthcare professionals with adequate quantities of N-95 respirator masks to address the ongoing health care crisis, as we are now entering the principal flu season particularly.?.. Alpha Pro Tech to triple N-95 respirator mask production Alpha Pro Tech, Ltd. As a total result of this anticipated demand, we will triple N-95 respirator mask creation starting in the beginning of the fourth quarter 2009, october 1 which begins, 2009.

Other Articles From "dermatology":

Random Articles